Royce & Associates’s Definium Therapeutics DFTX Stock Holding History

Royce & Associates’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.81M	Sell	208,551 -25,500	-11%	-$630K	0.08%	384
2026 Q1	$4.42M	Buy	234,051 +70,010	+43%	+$1.19M	0.04%	483
2025 Q4	$2.2M	Buy	164,041 +83,017	+102%	+$1.03M	0.02%	579
2025 Q3	$955K	Buy	+81,024	New	+$756K	0.01%	671

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Royce & Associates's DFTX Position: Q2 2026 in Review

Royce & Associates reduced its Definium Therapeutics (DFTX) stake by 11% in Q2 2026, selling an estimated $630K and leaving 208,551 shares worth $9.81M. The position accounts for 0.08% of the portfolio, ranked #384.

Royce & Associates first reported a position in DFTX in Q3 2025 and has held it in 4 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Royce & Associates held 208,551 shares of Definium Therapeutics worth $9.81M as of Q2 2026.
Royce & Associates sold 25,500 Definium Therapeutics shares in Q2 2026, an estimated $630K.
Definium Therapeutics made up 0.08% of Royce & Associates's portfolio in Q2 2026, its #384 holding.
Royce & Associates first reported a position in Definium Therapeutics in Q3 2025 and has held it in 4 quarters since.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.